

TDMS No. 20201 - 02

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]**

Date Report Reqsted: 06/14/2006

Test Type: 26-WEEK

TEF TRANSGENICS (PCB 126)

Time Report Reqsted: 15:08:25

Route: SKIN APPLICATION

CAS Number: 57465-28-8

First Dose M/F: NA / 04/21/03

Species/Strain: MICE/TG.AC HEMI

Lab: BAT

C Number: C20201B

Lock Date: 07/24/2004

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Test Type: 26-WEEK

Time Report Requested: 15:08:25

Route: SKIN APPLICATION

First Dose M/F: NA / 04/21/03

Species/Strain: MICE/TG.AC HEMI

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	360 NG/KG	1210 NG/KG	3600 NG/KG	7600 NG/KG
Disposition Summary					
Animals Initially in Study	20	20	20	20	20
Early Deaths					
Moribund Sacrifice	1	3	3	2	1
Natural Death	2	3	5	2	1
Survivors					
Natural Death		1			
Terminal Sacrifice	17	13	12	16	18
Animals Examined Microscopically	20	20	20	20	20
ALIMENTARY SYSTEM					
Gallbladder	(0)	(0)	(1)	(0)	(0)
Inflammation, Granulomatous			1 [3.0]		
Liver	(20)	(20)	(20)	(20)	(20)
Clear Cell Focus	1				
Fatty Change	1 [1.0]	2 [1.0]	2 [1.0]	1 [1.0]	2 [1.0]
Hematopoietic Cell Proliferation	1 [1.0]	1 [1.0]	1 [1.0]	2 [2.0]	10 [1.0]
Hepatodiaphragmatic Nodule	1				
Inflammation	19 [1.2]	17 [1.2]	14 [1.1]	18 [1.2]	19 [1.5]
Necrosis	7 [1.6]	8 [1.1]	6 [1.3]	6 [1.2]	13 [1.4]
Pigmentation	10 [1.0]	8 [1.0]	10 [1.1]	14 [1.0]	10 [1.0]
Mesentery	(1)	(0)	(0)	(2)	(0)
Artery, Thrombosis				1 [4.0]	
Fat, Necrosis	1 [3.0]			1 [3.0]	
Pancreas	(0)	(0)	(0)	(1)	(0)
Necrosis				1 [3.0]	
Artery, Inflammation, Chronic Active				1 [4.0]	
Salivary Glands	(1)	(0)	(0)	(0)	(1)
Stomach, Forestomach	(6)	(3)	(2)	(7)	(7)
Stomach, Glandular	(1)	(0)	(0)	(0)	(0)
Glands, Hyperplasia	1 [2.0]				
Tooth	(6)	(3)	(6)	(2)	(4)
CARDIOVASCULAR SYSTEM					

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Control data contained within this report was collected on study 20201-01

Test Type: 26-WEEK

TEF TRANSGENICS (PCB 126)

Time Report Requested: 15:08:25

Route: SKIN APPLICATION

CAS Number: 57465-28-8

First Dose M/F: NA / 04/21/03

Species/Strain: MICE/TG.AC HEMI

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	360 NG/KG	1210 NG/KG	3600 NG/KG	7600 NG/KG
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
Ovary	(1)	(1)	(0)	(0)	(0)
Uterus	(0)	(0)	(0)	(1)	(0)
Atrophy				1 [2.0]	
HEMATOPOIETIC SYSTEM					
Lymph Node	(0)	(1)	(0)	(0)	(0)
Lymph Node, Mandibular	(0)	(3)	(0)	(0)	(1)
Hyperplasia, Plasma Cell		2 [3.0]			1 [3.0]
Lymph Node, Mesenteric	(1)	(1)	(0)	(0)	(0)
Spleen	(20)	(20)	(20)	(20)	(20)
Hematopoietic Cell Proliferation	3 [1.3]		5 [1.0]	10 [1.7]	17 [2.1]
Necrosis				1 [3.0]	
Thymus	(20)	(19)	(19)	(20)	(20)
Atrophy	3 [2.7]	1 [2.0]	7 [2.6]	2 [4.0]	7 [2.9]
INTEGUMENTARY SYSTEM					
Skin	(4)	(5)	(5)	(5)	(6)
Fibrosis	1 [2.0]		2 [1.5]		
Hyperplasia, Squamous	4 [1.8]	2 [2.0]	1 [1.0]		4 [2.8]
Inflammation, Chronic Active	3 [1.3]	2 [2.5]	2 [1.0]	1 [2.0]	2 [2.0]
Ulcer	1 [1.0]				1 [2.0]
Skin, Control Dermis	(20)	(20)	(20)	(20)	(20)
Inflammation, Chronic Active		2 [1.0]			1 [1.0]
Skin, Control Epidermis	(20)	(20)	(20)	(20)	(20)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Control data contained within this report was collected on study 20201-01

Test Type: 26-WEEK

TEF TRANSGENICS (PCB 126)

Time Report Requested: 15:08:25

Route: SKIN APPLICATION

CAS Number: 57465-28-8

First Dose M/F: NA / 04/21/03

Species/Strain: MICE/TG.AC HEMI

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	360 NG/KG	1210 NG/KG	3600 NG/KG	7600 NG/KG
Hyperplasia, Squamous		2 [1.0]			
Skin, Site Of Application	(20)	(20)	(20)	(20)	(20)
Fibrosis	1 [2.0]				
Hyperplasia, Mast Cell					1 [2.0]
Hyperplasia, Squamous	1 [3.0]		3 [2.0]	8 [2.4]	14 [2.6]
Inflammation, Chronic Active	2 [1.0]		6 [1.3]	18 [1.9]	20 [2.2]
Ulcer			1 [1.0]		2 [3.0]
Skin, Soa No Mass	(20)	(20)	(20)	(19)	(16)
Hyperplasia, Squamous	1 [1.0]	3 [1.0]		3 [1.0]	6 [1.3]
Inflammation, Chronic Active	3 [1.0]	4 [1.0]	2 [1.0]	8 [1.0]	11 [1.1]
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
Brain	(0)	(0)	(1)	(0)	(0)
Meninges, Hemorrhage			1 [2.0]		
RESPIRATORY SYSTEM					
Lung	(20)	(20)	(20)	(20)	(20)
Alveolar Epithelium, Hyperplasia		1 [3.0]	1 [1.0]		
Alveolus, Infiltration Cellular, Histiocyte		1 [1.0]			1 [2.0]
Bronchiole, Inflammation					1 [1.0]
Interstitialium, Inflammation	1 [1.0]			1 [1.0]	3 [1.3]
Perivascular, Inflammation	2 [1.0]			1 [3.0]	2 [1.5]
Serosa, Inflammation, Chronic Active	7 [1.0]				1 [1.0]
SPECIAL SENSES SYSTEM					
Eye	(0)	(0)	(1)	(0)	(0)
Anterior Chamber, Cornea, Inflammation, Suppurative			1 [3.0]		
URINARY SYSTEM					

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Control data contained within this report was collected on study 20201-01

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	360 NG/KG	1210 NG/KG	3600 NG/KG	7600 NG/KG
Kidney	(0)	(0)	(1)	(0)	(0)

*** END OF REPORT ***